Clinical Trials
34 trialsNCT05784012 2026-06-04
RADIAN
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Phase 1/2 Active not recruiting
NCT03881098 2026-06-03
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy
University of Colorado, Denver
Phase NA Active not recruiting
NCT05048459 2026-06-02
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
Memorial Sloan Kettering Cancer Center
Phase NA Active not recruiting
NCT05681039 2026-06-02
Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03952585 2026-06-01
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
NCT04858269 2026-06-01
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
Wake Forest University Health Sciences
Phase 2 Active not recruiting
NCT05574101 2026-05-15
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05208944 2026-05-13
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Active not recruiting
NCT01512589 2026-04-15
Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01706939 2026-04-09
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
Icahn School of Medicine at Mount Sinai
Phase 3 Active not recruiting
NCT03737734 2026-04-06
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
Alpha Tau Medical LTD.
Phase NA Active not recruiting
NCT06236425 2026-04-01
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT03729518 2026-02-20
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
Abramson Cancer Center at Penn Medicine
Phase NA Active not recruiting
NCT04150900 2026-02-19
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck
University of Maryland, Baltimore
Phase 2 Active not recruiting
NCT06041802 2026-02-17
MK-3475A-E39
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04391049 2026-01-30
Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery
NRG Oncology
Phase 1 Active not recruiting
NCT05366166 2026-01-28
Pembrolizumab Plus Olaparib in LA-HNSCC
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05934929 2026-01-02
MARGINS
Centre Henri Becquerel
Phase NA Active not recruiting
NCT04124198 2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA Active not recruiting
NCT05858229 2025-12-31
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
Rochester Dermatologic Surgery
Phase 1/2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT02994069 2025-10-14
Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers
University of Kentucky
Phase 2 Active not recruiting
NCT07177638 2025-09-17
A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.
NYU Langone Health
Phase NA Active not recruiting
NCT05608876 2025-08-07
A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer
QBiotics Group Limited
Phase 2 Active not recruiting
NCT02817958 2025-06-26
MEGACEP
UNICANCER
Phase 2 Active not recruiting
NCT04305795 2025-06-19
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Rakuten Medical, Inc.
Phase 1/2 Active not recruiting
NCT03341936 2025-06-18
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03854032 2025-06-06
Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck
Thomas Jefferson University
Phase 2 Active not recruiting
NCT04808999 2025-05-29
Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC)
University of Pittsburgh
Phase 2 Active not recruiting
NCT04050436 2025-01-27
CERPASS
Replimune, Inc.
Phase 2 Active not recruiting
NCT05202860 2025-01-22
VAXAK
Bispebjerg Hospital
Phase 2 Active not recruiting
NCT03784066 2024-07-03
DUTRELASCO
Universitaire Ziekenhuizen KU Leuven
Phase 1/2 Active not recruiting
NCT03283605 2024-06-28
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 1/2 Active not recruiting